Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Oner Sanli"'
Autor:
Duygu Has Simsek, Zeynep Gözde Özkan, Fikret Büyükkaya, Oner Sanli, Emine Goknur Isik, Caner Civan, Mert Basaran, Serkan Kuyumcu, Yasemin Sanli
Publikováno v:
Clinical Nuclear Medicine. 46:943-951
Purpose Prostate-specific membrane antigen (PSMA)-targeted therapies are among the current promising treatments. We present our preliminary results on the use of 225Ac-PSMA therapy in patients with metastatic castration-resistant prostate cancer as a
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 48:1701-1705
Publikováno v:
Türk Üroloji Dergisi/Turkish Journal of Urology. 45:13-21
OBJECTIVE: To investigate the predictive factors of renal functional change at postoperative period and at last follow-up in patients undergoing elective and clamped laparoscopic partial nephrectomy (LPN) with limited (≤20 minutes) and overextended
Autor:
Murat Serilmez, Samed Verep, Kamranbay Gasimov, Oner Sanli, Yasin Yitgin, Faruk Özcan, Tzevat Tefik, Selcuk Erdem, Derya Duranyildiz
Publikováno v:
International journal of clinical practiceREFERENCES. 75(8)
Introduction: Matrix metalloproteinase-9 (MMP-9) has a role in the destruction of lamina propria (LP) of the bladder wall and SMAD-2 promotes cell-to-cell adhesion. This study aimed to investigate the association between LP invasion and serum protein
Autor:
Yuval Freifeld, Hans J. Hammers, Aditya Bagrodia, Laura Maria Krabbe, Yair Lotan, Vitaly Margulis, Oner Sanli, Nirmish Singla, Timothy Clinton, Ryan Hutchinson, Raquibul Hannan, James Brugarolas, Justin T. Matulay, Solomon L. Woldu
Publikováno v:
Clinical Genitourinary Cancer. 16:e1221-e1235
Background The optimal timing of targeted therapy (TT) initiation for metastatic renal-cell carcinoma (mRCC) is not clear. We used a nationwide cancer registry to determine clinical and social factors associated with delayed TT and to evaluate the as
Publikováno v:
Nuclear Medicine Communications. 39:871-880
Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/
Publikováno v:
Clinical Nuclear Medicine. 47:e54-e55
Herein we present 2 mCRPC (metastatic castration-resistant prostate cancer) patients who underwent 68Ga-PSMA PET/CT for PSMA-targeted radioligand therapy eligibility. Prior studies have noted aggressive clinical behavior and poor prognosis associated
Publikováno v:
Clinical Nuclear Medicine. 47:e45-e46
68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a well-established imaging modality in patients with prostate cancer; however, PSMA expression is also reported in the tumor-associated neovasculature, including but not limited to hepatocellul
Autor:
R. Aydin, Duygu Has Simsek, Yasemin Sanli, Faruk Özcan, Yasemin Ozluk, E. Degirmenci, Oner Sanli, Sidar Bagbudar, Selcuk Erdem
Publikováno v:
European Urology Open Science, Vol 21, Iss, Pp S134-S137 (2020)
Publikováno v:
European Urology Open Science, Vol 21, Iss, Pp S118-S122 (2020)